Is Prestige Consumer Healthcare, Inc. overvalued or undervalued?

As of 7 August 2025, the valuation grade for Prestige Consumer Healthcare, Inc. moved from fair to attractive, indicating a positive shift in its perceived value. The company appears to be undervalued based on its current metrics, with a P/E ratio of 20, a Price to Book Value of 2.48, and an EV to EBITDA of 14.39. In comparison, peers such as Alkermes Plc have a P/E of 13.77, and ACADIA Pharmaceuticals, Inc. has a higher P/E of 19.28, suggesting that Prestige may offer better value relative to its earnings potential.
Despite recent stock performance lagging behind the S&P 500, with a year-to-date return of -17.92% compared to the S&P 500's 12.22%, the long-term outlook remains promising, as evidenced by a 3-year return of 24.47% versus the S&P 500's 70.41%. Overall, these metrics and comparisons suggest that Prestige Consumer Healthcare, Inc. is positioned as an attractive investment opportunity within its industry.